Inclusion criteria:
Adults (defined) as older than 18 years and younger than 60 years
Laboratory confirmation of Covid19 infection with reverse transcription polymerase chain reaction (RT-PCR) from oropharyngeal or nasopharyngeal swab
Covid19-related new organ dysfunction, including hypoxia due to the need for supplemental oxygen to maintain oxygen saturation greater than 94%, hypotension (systolic blood pressure less than 90 mm Hg) or the need for vasopressor, an inotropic drug ( Renal impairment (increase in creatinine by more than 50% from baseline, decrease in glomerular filtration rate by more than 25% from onset or urination less than 0.5 ml / kg for 6 hours, decrease in Glasgow scale by 2 or more, ie 13 or less Out of 15 points, thrombocytopenia less than 150,000 platelets per millimeter, gastrointestinal symptoms requiring hospitalization (eg severe nausea, vomiting, diarrhea or abdominal pain)
Exclusion criteria:
Sensitivity or sensitivity to Lopinavir or Ritonavir or recombinant IFN-β1b, including, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema or angioedema syndrome.
Use of drugs that are contraindicated with lopinavir/ritonavir and should not be substituted or discontinued during the study period, such as inhibitors CYP3A
Pregnancy-Eligible female participants of childbearing age are tested for pregnancy before enrolling in the study
HIV infection is known to cause concern about the resistance to lepinavir / ritonavir if used in combination with other anti-HIV drugs.
Hemoglobin under 8
Known heart failure EF under 50%
According to the 31st National Guide, all vulnerable groups, such as the mentally disabled, emergency patients, or prisoners, are excluded from the study.